Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The presentation, dated January 2026, is provided as Exhibit 99.1 to this report and is incorporated into the report by reference.
The company notes that the presentation and related information are being furnished, not filed, which means they are not subject to certain liability provisions under federal securities laws and will not automatically be incorporated into other SEC documents.
Neumora Therapeutics, Inc. reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option covering 350,000 shares of common stock on January 8, 2026. The option has an exercise price of $2.33 per share and is held directly. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported a Form 4 transaction for officer Daljit Singh Aurora, its Chief Operating and Development Officer. On January 8, 2026, Aurora received a stock option to buy 750,000 shares of common stock at an exercise price of $2.33 per share, with no cost reported for the option itself.
All 750,000 derivative securities are shown as beneficially owned directly after the grant. The option vests over four years: 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the option is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026. These options give him the right to buy those shares at an exercise price of $2.33 per share. The grant was reported as a direct beneficial ownership position, with 750,000 derivative securities held after the transaction.
According to the vesting terms, 25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years. This structure means the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date, aligning the officer’s potential equity ownership with longer-term service to the company.
Neumora Therapeutics, Inc. reported a new equity award for President Joshua PintoJanuary 8, 2026, he was granted an option to purchase 1,200,000 shares of common stock at an exercise price of $2.33 per share. According to the vesting terms, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
Neumora Therapeutics, Inc. reported that Chief Executive Officer and Chairman of the Board Paul L. Berns received a grant of stock options on January 8, 2026. The Form 4 shows an award of 1,650,000 stock options, each with an exercise price of $2.33 per share, giving him the right to buy common stock at that price. The options were acquired as a derivative security and are held directly, with 1,650,000 derivative securities beneficially owned following the transaction.
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the entire grant is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported that its lender K2 HealthVentures exercised a conversion right under an existing Loan and Security Agreement. K2 HealthVentures converted $2.5 million of term loan principal into common stock at a price of $0.8774 per share, as allowed under the agreement that permits conversion of up to $12.5 million of principal. On November 20, 2025, Neumora issued 2,849,327 shares of common stock to K2 HealthVentures Equity Trust LLC in connection with this conversion. The shares were issued as a private offering relying on the registration exemption in Section 4(a)(2) of the Securities Act of 1933.
Neumora Therapeutics (NMRA) officer Daljit Singh Aurora reported an open-market sale of 114,703 shares of common stock on 11/11/2025 at a weighted average price of $2.6767. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024, and the sold shares were held by the Aurora Family Trust. Following the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.
Neumora Therapeutics reported a Q3 2025 net loss of $56.8 million, with nine‑month net loss at $177.5 million. Operating expenses fell year over year as research and development declined to $40.5 million from $60.6 million, and general and administrative to $12.2 million from $16.0 million. The company recorded $5.0 million of acquired in‑process R&D tied to its Vanderbilt M4 program.
Cash, cash equivalents and marketable securities totaled $171.5 million as of September 30, 2025. Neumora believes this will fund operations for at least the next 12 months. In May, it drew $20.0 million from a term loan facility with K2 HealthVentures (up to $125.0 million across tranches) at a minimum rate of 10.45%, and subsequently borrowed an additional $40.0 million after quarter‑end.
The pipeline includes a Phase 3 program for navacaprant in major depressive disorder and a Phase 1b study for NMRA‑511 in agitation due to Alzheimer’s disease, with early‑stage M4 PAM candidates advancing. Shares outstanding were 167,089,114 as of November 1, 2025.
Neumora Therapeutics, Inc. furnished an 8-K stating it announced financial results for the second quarter ended September 30, 2025. The full details are provided in a press release attached as Exhibit 99.1.
The company notes that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. The report was signed by Chief Financial Officer Michael Milligan on November 6, 2025.